173 related articles for article (PubMed ID: 25465943)
1. RAC1 and melanoma.
Halaban R
Clin Ther; 2015 Mar; 37(3):682-5. PubMed ID: 25465943
[TBL] [Abstract][Full Text] [Related]
2. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Watson IR; Li L; Cabeceiras PK; Mahdavi M; Gutschner T; Genovese G; Wang G; Fang Z; Tepper JM; Stemke-Hale K; Tsai KY; Davies MA; Mills GB; Chin L
Cancer Res; 2014 Sep; 74(17):4845-4852. PubMed ID: 25056119
[TBL] [Abstract][Full Text] [Related]
3. RAC1
Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
[TBL] [Abstract][Full Text] [Related]
4. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
[TBL] [Abstract][Full Text] [Related]
6. Targeting effector pathways in RAC1
Uribe-Alvarez C; Guerrero-Rodríguez SL; Rhodes J; Cannon A; Chernoff J; Araiza-Olivera D
Small GTPases; 2021 Jul; 12(4):273-281. PubMed ID: 32043900
[TBL] [Abstract][Full Text] [Related]
7. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
[TBL] [Abstract][Full Text] [Related]
8. RAC1P29S is a spontaneously activating cancer-associated GTPase.
Davis MJ; Ha BH; Holman EC; Halaban R; Schlessinger J; Boggon TJ
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):912-7. PubMed ID: 23284172
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic Differences of Activation of Rac1
Senyuz S; Jang H; Nussinov R; Keskin O; Gursoy A
J Phys Chem B; 2021 Apr; 125(15):3790-3802. PubMed ID: 33848152
[TBL] [Abstract][Full Text] [Related]
10. RAC1 as a Therapeutic Target in Malignant Melanoma.
Cannon AC; Uribe-Alvarez C; Chernoff J
Trends Cancer; 2020 Jun; 6(6):478-488. PubMed ID: 32460002
[TBL] [Abstract][Full Text] [Related]
11. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
Araiza-Olivera D; Feng Y; Semenova G; Prudnikova TY; Rhodes J; Chernoff J
Oncogene; 2018 Feb; 37(7):944-952. PubMed ID: 29059171
[TBL] [Abstract][Full Text] [Related]
12. Impact of point mutation P29S in RAC1 on tumorigenesis.
Rajendran V; Gopalakrishnan C; Purohit R
Tumour Biol; 2016 Nov; 37(11):15293-15304. PubMed ID: 27699663
[TBL] [Abstract][Full Text] [Related]
13. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
Foth M; Parkman G; Battistone B; McMahon M
Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
[TBL] [Abstract][Full Text] [Related]
14. DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1
Tomino T; Tajiri H; Tatsuguchi T; Shirai T; Oisaki K; Matsunaga S; Sanematsu F; Sakata D; Yoshizumi T; Maehara Y; Kanai M; Cote JF; Fukui Y; Uruno T
Biochem Biophys Res Commun; 2018 Feb; 497(1):298-304. PubMed ID: 29432733
[TBL] [Abstract][Full Text] [Related]
15. RAC1 P29S regulates PD-L1 expression in melanoma.
Vu HL; Rosenbaum S; Purwin TJ; Davies MA; Aplin AE
Pigment Cell Melanoma Res; 2015 Sep; 28(5):590-8. PubMed ID: 26176707
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
17. Characterisation and outcome of RAC1 mutated melanoma.
Lodde GC; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Sucker A; Placke JM; Zaremba A; Albrecht LJ; Kowall B; Galetzka W; Becker JC; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Schadendorf D; Ugurel S; Griewank K
Eur J Cancer; 2023 Apr; 183():1-10. PubMed ID: 36773463
[TBL] [Abstract][Full Text] [Related]
18. Developments in targeted therapy in melanoma.
Amann VC; Ramelyte E; Thurneysen S; Pitocco R; Bentele-Jaberg N; Goldinger SM; Dummer R; Mangana J
Eur J Surg Oncol; 2017 Mar; 43(3):581-593. PubMed ID: 27923592
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
20. A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression.
Chong SJF; Lai JXH; Qu J; Hirpara J; Kang J; Swaminathan K; Loh T; Kumar A; Vali S; Abbasi T; Pervaiz S
Cancer Lett; 2019 Aug; 457():151-167. PubMed ID: 31103719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]